Last reviewed · How we verify
Dexamethasone Phosphate Ophthalmic Solution
At a glance
| Generic name | Dexamethasone Phosphate Ophthalmic Solution |
|---|---|
| Also known as | EGP-437, dexafree, Active arm, Arm 1, 40 mg/mL Dexamethasone Phosphate Ophthalmic, OCS-01 |
| Sponsor | Eyegate Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Efficacy and Safety Study of DFL24498 in the Treatment of AKC (PHASE3)
- Study of TN-001 Topical Eyedrops for Keratoconus (PHASE1, PHASE2)
- Parasitic Ulcer Treatment Trial (PHASE3)
- PRO-232 in Patients Subjected to Cataract Surgery (PHASE3)
- Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. (PHASE1)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- Three Different Modalities for Treatment of Inflammatory Punctal Stenosis (NA)
- Lubricating Eye Drops After Routine Cataract Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: